OR WAIT null SECS
© 2022 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
Sylvia Findlay is Pharmaceuticals and Biotechnology Industry Analyst at Frost & Sullivan.
December 01, 2006
Why do the biotech ventures mange to have such promising drug candidates while pharmaceutical R&D is facing a drug deficit?
January 01, 2006
FDA has tightened up the approval of new drugs, ensuring careful scrutiny of clinical data and stringent scanning to analyse the probable side-effects of a new drug